BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 32274724)

  • 1. Non-Anticoagulant Heparins as Heparanase Inhibitors.
    Cassinelli G; Torri G; Naggi A
    Adv Exp Med Biol; 2020; 1221():493-522. PubMed ID: 32274724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
    Naggi A; Casu B; Perez M; Torri G; Cassinelli G; Penco S; Pisano C; Giannini G; Ishai-Michaeli R; Vlodavsky I
    J Biol Chem; 2005 Apr; 280(13):12103-13. PubMed ID: 15647251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases.
    Rivara S; Milazzo FM; Giannini G
    Future Med Chem; 2016 Apr; 8(6):647-80. PubMed ID: 27057774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparanase procoagulant effects and inhibition by heparins.
    Nadir Y; Brenner B
    Thromb Res; 2010 Apr; 125 Suppl 2():S72-6. PubMed ID: 20434010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.
    Barash U; Cohen-Kaplan V; Dowek I; Sanderson RD; Ilan N; Vlodavsky I
    FEBS J; 2010 Oct; 277(19):3890-903. PubMed ID: 20840586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties.
    Lapierre F; Holme K; Lam L; Tressler RJ; Storm N; Wee J; Stack RJ; Castellot J; Tyrrell DJ
    Glycobiology; 1996 Apr; 6(3):355-66. PubMed ID: 8724143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells.
    Irimura T; Nakajima M; Nicolson GL
    Biochemistry; 1986 Sep; 25(18):5322-8. PubMed ID: 3768351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-anticoagulant heparins and inhibition of cancer.
    Casu B; Vlodavsky I; Sanderson RD
    Pathophysiol Haemost Thromb; 2008; 36(3-4):195-203. PubMed ID: 19176992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Aspects of Heparanase Interaction with Heparan Sulfate, Heparin and Glycol Split Heparin.
    Elli S; Guerrini M
    Adv Exp Med Biol; 2020; 1221():169-188. PubMed ID: 32274710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase.
    Levy-Adam F; Abboud-Jarrous G; Guerrini M; Beccati D; Vlodavsky I; Ilan N
    J Biol Chem; 2005 May; 280(21):20457-66. PubMed ID: 15760902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer.
    Casu B; Naggi A; Torri G
    Matrix Biol; 2010 Jul; 29(6):442-52. PubMed ID: 20416374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-heparanase activity of ultra-low-molecular-weight heparin produced by physicochemical depolymerization.
    Achour O; Poupard N; Bridiau N; Bordenave Juchereau S; Sannier F; Piot JM; Fruitier Arnaudin I; Maugard T
    Carbohydr Polym; 2016 Jan; 135():316-23. PubMed ID: 26453883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
    Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
    Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparanase, tissue factor, and cancer.
    Nadir Y; Vlodavsky I; Brenner B
    Semin Thromb Hemost; 2008 Mar; 34(2):187-94. PubMed ID: 18645924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparanase involvement in physiology and disease.
    Nasser NJ
    Cell Mol Life Sci; 2008 Jun; 65(11):1706-15. PubMed ID: 18425416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of heparanase inhibitors in cancer therapy.
    Heyman B; Yang Y
    Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
    Ritchie JP; Ramani VC; Ren Y; Naggi A; Torri G; Casu B; Penco S; Pisano C; Carminati P; Tortoreto M; Zunino F; Vlodavsky I; Sanderson RD; Yang Y
    Clin Cancer Res; 2011 Mar; 17(6):1382-93. PubMed ID: 21257720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species.
    Bar-Ner M; Eldor A; Wasserman L; Matzner Y; Cohen IR; Fuks Z; Vlodavsky I
    Blood; 1987 Aug; 70(2):551-7. PubMed ID: 2955820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase.
    Pala D; Rivara S; Mor M; Milazzo FM; Roscilli G; Pavoni E; Giannini G
    Glycobiology; 2016 Jun; 26(6):640-54. PubMed ID: 26762172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins.
    Hostettler N; Naggi A; Torri G; Ishai-Michaeli R; Casu B; Vlodavsky I; Borsig L
    FASEB J; 2007 Nov; 21(13):3562-72. PubMed ID: 17557930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.